BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
BIOMERICA INC
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026
$1.76−0.09 (-4.86%)
Close on Oct 19, 2026
- Market cap
- $5.80M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
8.1%+3.0 pts over 5 years
Operating margin
-119.5%−15.3 pts over 5 years
Net margin
-84.8%+18.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -16.2% | -5.9% | -9.2% | -1.4% | |
| Gross profit | -27.3% | -6.7% | -0.2% | -13.4% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -18.7% | -63.5% | -112.1% | |
| Return on assets | -16.9% | -51.2% | -59.4% | |
| Current ratio | 7.96 | 7.10 | 1.62 | |
| Interest coverage | -3385.2× | -20435.1× | – | |
| Inventory turnover | 2.1× | 2.3× | 2.6× | |
| Capex to revenue | 1.7% | 1.9% | – | |
| Diluted shares | 1M | 1M | 3M |
Cash use needs five years of cash flow figures
Biomerica does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-84.8%
×Asset turnover0.70×
×Equity multiplier1.89×
=Return on equity, FY2026-112.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -84.8% | 0.70× | 1.89× | -112.1% |
| FY2025 | -93.6% | 0.70× | 1.42× | -93.0% |
| FY2024 | -110.4% | 0.46× | 1.29× | -65.3% |
| FY2023 | -133.7% | 0.41× | 1.29× | -71.2% |
| FY2022 | -24.0% | 1.63× | 1.32× | -51.6% |
| FY2021 | -103.4% | 0.50× | 1.24× | -63.5% |
| FY2020 | -40.0% | 0.59× | 1.24× | -29.4% |
| FY2019 | -46.0% | 0.99× | 1.26× | -57.6% |
| FY2018 | -26.3% | 1.09× | 1.16× | -33.3% |
| FY2017 | -15.7% | 1.08× | 1.11× | -18.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
2of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$3.78M
- Cash generatingOperating cash flow above zero-$3.42M
- Return on assets improvedROA up on the prior year-53.7% → -63.5%
- Earnings backed by cashOperating cash flow above net income-$3.42M vs -$3.78M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.80 → 1.62
- No dilutionShare count did not rise2M → 3M
- Gross margin improvedGross margin up on the prior year9.38% → 8.13%
- More efficientAsset turnover rose0.57 → 0.75